CPC-078 Ipilimumab For Advanced Melanoma: Drug Use Review
نویسندگان
چکیده
منابع مشابه
Ipilimumab for advanced melanoma: a nursing perspective.
PURPOSE/OBJECTIVES To discuss the response patterns and side effects related to ipilimumab, a new immunotherapeutic agent under investigation in the treatment of advanced melanoma and other malignancies. DATA SOURCES Published articles, abstracts, research data, and clinical experience. DATA SYNTHESIS Ipilimumab is a fully human monoclonal antibody that inhibits the activity of cytotoxic T-...
متن کاملIpilimumab for advanced melanoma: A pharmacologic perspective
Ipilimumab, a fully human anti-CTLA-4 antibody, has been approved for the treatment of unresectable or metastatic melanoma based on its survival benefit demonstrated in randomized phase III studies. The current approved dosing schedule of ipilimumab is 3 mg/kg as a 90-min intravenous infusion every 3 weeks for a total of 4 doses. The immune-mediated mechanism of action of ipilimumab can result ...
متن کاملIpilimumab (Yervoy) Prolongs Survival in Advanced Melanoma
INTRODUCTION Melanoma, a cancer originating in melanocytes, is the most deadly form of skin cancer and the sixth leading type of cancer in the U.S.1 According to the World Health Organization, approximately 53,000 people die of melanoma each year worldwide.2 In 2011, an estimated 70,230 adults were diagnosed with melanoma in the U.S., and 8,790 died of the disease.3,4 This may be an underestima...
متن کاملNivolumab plus ipilimumab in the treatment of advanced melanoma
Advanced melanoma has historically been a difficult disease to treat due to few effective systemic treatment options. However, over the past few years, scientific advancements in immune checkpoint inhibition have resulted in several novel approaches that have changed front-line management of advanced melanoma. Despite these exciting developments, there remains room for improvement in treatment ...
متن کاملSingle-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting
BACKGROUND : Ipilimumab is a monoclonal antibody that antagonizes cytotoxic T lymphocyte antigen-4, a negative regulator of the immune system. The authors report on advanced refractory melanoma patients treated in a compassionate use trial of ipilimumab at the Memorial Sloan-Kettering Cancer Center. METHODS : Patients with advanced refractory melanoma were treated in a compassionate use trial...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Journal of Hospital Pharmacy
سال: 2013
ISSN: 2047-9956,2047-9964
DOI: 10.1136/ejhpharm-2013-000276.535